Moreover, it has been reported that vascular endothelial growth factor (VEGF) expression increased in systemic AL amyloidosis [10] and that bevacizumab (a monoclonal antibody against VEGF) was effective in the management of refractory pleural effusion [4,5]. This evidence concerns the gene VEGFA and primary systemic amyloidosis.